Press Releases + News

Date	Title and Summary	View
Toggle SummaryAug 07, 2014	Galectin Therapeutics Reports Second Quarter 2014 Financial Results	View HTML Galectin Therapeutics Reports Second Quarter 2014 Financial Results 28.9 KB
Toggle SummaryAug 05, 2014	Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter Patent Covers Use of Company's Galectin Inhibitor in NASH, Fibrotic Diseases, Cancer and Other Disorders in Which Galectins are Involved in Pathogenesis	View HTML Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 18.8 KB
Toggle SummaryAug 04, 2014	Galectin Therapeutics Responds to Class Action Lawsuit	View HTML Galectin Therapeutics Responds to Class Action Lawsuit 14.3 KB
Toggle SummaryJul 30, 2014	Galectin Therapeutics Issues Statement on GR-MD-02 Development Program	View HTML Galectin Therapeutics Issues Statement on GR-MD-02 Development Program 22.7 KB
Toggle SummaryJul 25, 2014	Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis Webcast Scheduled for Tuesday, July 29, 2014, 8:30 a.m. Eastern Daylight Time	View HTML Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 19.7 KB
Toggle SummaryJul 22, 2014	Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma Trial Conducted by Providence Portland Medical Center, a Leading Cancer Immunotherapy Research Institute	View HTML Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma 19.6 KB
Toggle SummaryJul 09, 2014	Galectin Therapeutics Added to Russell 2000 Index	View HTML Galectin Therapeutics Added to Russell 2000 Index 16.4 KB
Toggle SummaryJun 23, 2014	Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 is Efficacious in Preclinical Model of Fatty Liver Disease With Fibrosis	View HTML Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 is Efficacious in Preclinical Model of Fatty Liver Disease With Fibrosis 20.4 KB
Toggle SummaryMay 29, 2014	Galectin Therapeutics to Present at Jefferies 2014 Global Healthcare Conference	View HTML Galectin Therapeutics to Present at Jefferies 2014 Global Healthcare Conference 13.7 KB
Toggle SummaryMay 28, 2014	Galectin Therapeutics Receives U.S. Patent for GR-MD-02 in Diabetic Nephropathy, a Progressive Kidney Disease	View HTML Galectin Therapeutics Receives U.S. Patent for GR-MD-02 in Diabetic Nephropathy, a Progressive Kidney Disease 16.1 KB